About AiCuris
AiCuris is a Healthcare company based in Wuppertal (Germany) founded in 2006, and was acquired by Asahi Kasei in February 2026. Antiviral and antibacterial therapeutics for infectious diseases are developed. AiCuris has raised $74.8 million across 4 funding rounds from investors including Asahi Kasei. The company has 61 employees. Its chief executive, as recorded, is Holger Zimmermann. AiCuris offers products and services including AIC468 and Pipeline Products. Its focus areas include Life Sciences, Infectious Diseases, Drugs and Viral. Its legal entity is AiCuris Anti-infective Cures GmbH.
Company details
AiCuris was established in 2006 in Wuppertal, Germany, as a pharmaceutical firm focused on antiviral and antibacterial agents targeting life-threatening infections. Therapeutics in the pipeline include Prevymis (AIC246), a quinazoline-based CMV terminase inhibitor approved for human cytomegalovirus treatment; AIC316, advanced to phase II for herpes simplex; and AIC649, in phase I for hepatitis B virus. Operations center on drug development for unmet needs in infectious diseases.
- Headquarters Wuppertal, Germany
- Employees 61
- Stage Acquired
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website aicuris.com
- Social LinkedIn X
- Acquired by Asahi Kasei (Feb 2026)
- Legal Name Aicuris Anti-Infective Cures Gmbh
- Annual Revenue$69.77 M (USD)-48as on Dec 31, 2018
- Net Profit$10.06 M (USD)-74as on Dec 31, 2019
- EBITDA$10.06 M (USD)-74as on Dec 31, 2019
- Total Equity Funding$74.8M (USD)
in 4 rounds
- Investors
- Employee Count61
- Acquired byAsahi Kasei
(Feb 2026)
Products & Services of AiCuris
AiCuris offers a comprehensive portfolio of products and services, including AIC468 and Pipeline Products.
Targets BK Virus infections in kidney transplant recipients.
Advances anti-viral therapies for immunocompromised patients.
Funding Insights of AiCuris
AiCuris has successfully raised a total of $74.8M across 4 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $74.8M
- Total Rounds 4
- First Round $74.8M
(Apr 2010)
All 4 funding rounds of AiCuris with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2017 | Grant | – | – | – | |
| Jan 2017 | $262,323 | Grant | – | – | – |
| Mar 2015 | $278,113 | Grant | – | – | – |
| Apr 2010 | $74.8M | Series B | – | – | – |
1 investors in total: 1 institutional.
Investors in AiCuris
AiCuris has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Asahi Kasei.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
CDMO focused on manufacturing of liquid, solid & injectable drug formulations | 1931 | asahi-kasei.com | Tokyo, Japan |
Investor details for AiCuris
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of AiCuris
1 people are tracked at AiCuris (1 in leadership); the tracked headcount is 61.
| Name | Role | Group |
|---|---|---|
Holger Zimmermann | CEO | Leadership |
Complete people profiles for AiCuris
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of AiCuris
4 dated milestones of AiCuris across 20 years, from founding to its latest funding, stage changes and deals.
- Founded AiCuris is founded.
- Funding First funding round of $74.8M.
- Funding Latest funding round, Grant,.
- Exit Acquired by Asahi Kasei.
Web traffic of AiCuris
The website of AiCuris (aicuris.com) receives about 3.2K visits a month and ranks #5,674,145 among all websites worldwide, #6,194 in Biotechnology and Pharmaceuticals.
- Monthly visits3.2K
▲ 11.7% vs previous month
- Unique visitors1.2K
per month
- Global rank#5,674,145
among all websites
- Category rank#6,194
Health · Biotechnology and Pharmaceuticals
- Bounce rate36%
- Pages per visit1.8
- Average visit44 sec
- DevicesDesktop 24% · Mobile 76%
Websites whose visitors overlap most with AiCuris. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| vical.com | 100% | View details | |||
| ariad.com | 94% | View details | |||
| fourrts.com | 89% | 13.9K | #2,054,904 | View details | |
| unichemlabs.com | 88% | 4.6K | #3,871,645 | View details | |
| sciformix.com | 88% | View details | |||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 11 similar websites and full traffic analytics for AiCuris
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 11 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Aicuris
Complete news archive for AiCuris
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about AiCuris
AiCuris was founded in 2006 and raised its 1st funding round 4 years after it was founded.
AiCuris is headquartered in Wuppertal, Germany. It is registered at Wuppertal, North Rhine-westphalia, Germany.
Holger Zimmermann is the CEO of AiCuris, as recorded in our data.
AiCuris is a funded company, having raised a total of $74.8M across 4 funding rounds to date. The company's 1st funding round was a Series B of $74.8M, raised on Apr 2010.
AiCuris has 61 employees.
Annual revenue of AiCuris is $69.77M as on Dec 31, 2018.
AiCuris was established in 2006 in Wuppertal, Germany, as a pharmaceutical firm focused on antiviral and antibacterial agents targeting life-threatening infections. Therapeutics in the pipeline include Prevymis (AIC246), a quinazoline-based CMV terminase inhibitor approved for human cytomegalovirus treatment; AIC316, advanced to phase II for herpes simplex; and AIC649, in phase I for hepatitis B virus. Operations center on drug development for unmet needs in infectious diseases.
AiCuris offers AIC468 and Pipeline Products.
AiCuris has 1 investor. Key investors include Asahi Kasei.
AiCuris operates through Aicuris Anti-Infective Cures Gmbh.
Yes. AiCuris was acquired by Asahi Kasei in February 2026.